This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Genetics, Other  • Cardiovascular Disease/ Myocardial Infarction  • Alert me on articles by topic

₂-Adrenergic Receptor Genotype and Survival After Acute Coronary Syndrome

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: The article by Dr Lanfear and colleagues¹ highlights the importance of detailed mechanistic studies examining common single nucleotide polymorphisms to determine phenotypic differences that may have clinically significant implications. The authors note that -blockade has been shown to reduce all-cause mortality after myocardial infarction. Their study showed that patients with an acute coronary syndrome who had the arginine allele (A) at nucleotide 46 of the ₂-adrenergic receptor (ADRB2) had significantly greater incidence of mortality than patients with the glycine (G) allele at this position following hospital discharge with prescribed -blockers.

While research on the ADRB2s remains controversial, the results of this study add to a growing body of in vivo evidence that persons homozygous for G at nucleotide 46 have enhanced receptor function compared with persons homozygous for A at this position.² The authors suggest that the effects of the A alleles "may represent . . . [Full Text of this Article]

Eric M. Snyder, PhD
snyder.eric@mayo.edu

Bruce D. Johnson, PhD
Division of Cardiovascular Diseases
Mayo Clinic and Foundation
Rochester, Minn

RELATED ARTICLES

₂-Adrenergic Receptor Genotype and Survival After Acute Coronary Syndrome
Catherine M. Jackson and Brian J. Lipworth
JAMA. 2006;295(7):757.
EXTRACT | FULL TEXT  

₂-Adrenergic Receptor Genotype and Survival After Acute Coronary Syndrome—Reply
David E. Lanfear, John A. Spertus, and Howard L. McLeod
JAMA. 2006;295(7):757-758.
EXTRACT | FULL TEXT  

₂-Adrenergic Receptor Genotype and Survival Among Patients Receiving -Blocker Therapy After an Acute Coronary Syndrome
David E. Lanfear, Philip G. Jones, Sharon Marsh, Sharon Cresci, Howard L. McLeod, and John A. Spertus
JAMA. 2005;294(12):1526-1533.
ABSTRACT | FULL TEXT